EA202190077A1 - Ингибиторы гистондеацетилазы - Google Patents

Ингибиторы гистондеацетилазы

Info

Publication number
EA202190077A1
EA202190077A1 EA202190077A EA202190077A EA202190077A1 EA 202190077 A1 EA202190077 A1 EA 202190077A1 EA 202190077 A EA202190077 A EA 202190077A EA 202190077 A EA202190077 A EA 202190077A EA 202190077 A1 EA202190077 A1 EA 202190077A1
Authority
EA
Eurasian Patent Office
Prior art keywords
histone deacetylase
deacetylase inhibitors
hdacs
compositions
useful
Prior art date
Application number
EA202190077A
Other languages
English (en)
Inventor
Нейтан Оливер Фуллер
Джон А. Лове III
Original Assignee
Алкермес, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алкермес, Инк. filed Critical Алкермес, Инк.
Publication of EA202190077A1 publication Critical patent/EA202190077A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящей заявке представлены соединения формулы (I)и их фармацевтически приемлемые соли и композиции, которые применимы для лечения различных состояний, связанных с гистондеацетилазами (HDAC).
EA202190077A 2018-07-13 2019-07-12 Ингибиторы гистондеацетилазы EA202190077A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697498P 2018-07-13 2018-07-13
PCT/US2019/041592 WO2020014605A1 (en) 2018-07-13 2019-07-12 Inhibitors of histone deacetylase

Publications (1)

Publication Number Publication Date
EA202190077A1 true EA202190077A1 (ru) 2021-08-30

Family

ID=67480370

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190077A EA202190077A1 (ru) 2018-07-13 2019-07-12 Ингибиторы гистондеацетилазы

Country Status (15)

Country Link
US (1) US20210276978A1 (ru)
EP (1) EP3820859B1 (ru)
JP (2) JP7414820B2 (ru)
KR (1) KR20210031704A (ru)
CN (1) CN112424184A (ru)
AR (1) AR115768A1 (ru)
AU (1) AU2019300036A1 (ru)
CA (1) CA3106355A1 (ru)
EA (1) EA202190077A1 (ru)
IL (2) IL309951A (ru)
MA (1) MA53129A (ru)
MX (1) MX2021000468A (ru)
SG (1) SG11202012916WA (ru)
TW (1) TWI809146B (ru)
WO (1) WO2020014605A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
PL3570834T3 (pl) 2017-01-11 2022-05-23 Alkermes, Inc. Bicykliczne inhibitory deacetylazy histonowej
RS63343B1 (sr) 2017-08-07 2022-07-29 Alkermes Inc Biciklični inhibitori histonske deacetilaze

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101808518A (zh) * 2007-06-27 2010-08-18 默沙东公司 作为组蛋白脱乙酰酶抑制剂的吡啶基和嘧啶基衍生物
WO2012149540A1 (en) * 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
WO2016018795A1 (en) * 2014-07-28 2016-02-04 The General Hospital Corporation Histone deacetylase inhibitors
HUE057041T2 (hu) * 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
TWI794171B (zh) * 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US10385031B2 (en) * 2016-11-23 2019-08-20 Regenacy Pharmaceuticals, Llc Substituted piperazines as selective HDAC1,2 inhibitors

Also Published As

Publication number Publication date
AR115768A1 (es) 2021-02-24
AU2019300036A1 (en) 2021-01-14
WO2020014605A1 (en) 2020-01-16
IL309951A (en) 2024-03-01
EP3820859C0 (en) 2024-03-20
US20210276978A1 (en) 2021-09-09
JP7414820B2 (ja) 2024-01-16
CN112424184A (zh) 2021-02-26
IL279940A (en) 2021-03-01
TW202019903A (zh) 2020-06-01
MX2021000468A (es) 2021-06-23
EP3820859B1 (en) 2024-03-20
JP2024038202A (ja) 2024-03-19
EP3820859A1 (en) 2021-05-19
CA3106355A1 (en) 2020-01-16
JP2021531336A (ja) 2021-11-18
MA53129A (fr) 2021-05-19
IL279940B1 (en) 2024-02-01
SG11202012916WA (en) 2021-01-28
TWI809146B (zh) 2023-07-21
KR20210031704A (ko) 2021-03-22

Similar Documents

Publication Publication Date Title
EA201792255A1 (ru) Ингибиторы деацетилаз гистонов и композиции и способы их применения
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
CY1123260T1 (el) Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου
EA201792673A1 (ru) 3-арил-4-амидобициклические [4,5,0] гидроксамовые кислоты в качестве ингибиторов hdac
EA202091774A1 (ru) Гербицидно-активные 3-фенилизоксазолин-5-карбоксамиды производных циклопентенилкарбоновой кислоты
EA202091479A1 (ru) Арил- и гетероарилзамещенные индольные соединения
CY1126110T1 (el) Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6
EA202190070A1 (ru) Бициклические ингибиторы гистондеацетилазы
MD3570834T2 (ro) Inhibitori biciclici ai histon deacetilazei
EA202190077A1 (ru) Ингибиторы гистондеацетилазы
EA201792028A1 (ru) Альфа-цинамидные соединения и композиции как ингибиторы hdac8
GEP20227443B (en) Magl inhibitors
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
EA201792247A1 (ru) Ингибиторы деацетилаз гистонов и композиции и способы их применения
EA201991700A1 (ru) Селективные ингибиторы jak1
EA202191519A1 (ru) Модуляторы trex1
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
MX2019007346A (es) Inhibidores de histona deacetilasa.
MX2020001484A (es) Inhibidores bicíclicos de la histona desacetilasa.
EA201590028A1 (ru) Ингибиторы гистондеацетилазы и их композиции и способы их применения
BR112017028139A2 (pt) inibidores de histona desacetilase
MX370142B (es) Inhibidores de hdac.
EA201991542A1 (ru) Бициклические ингибиторы деацетилазы гистонов
EA202190452A1 (ru) Ингибиторы cdk8/19